Xeris Biopharma Holdings (XERS) Inventory Average (2021 - 2026)

Xeris Biopharma Holdings' Inventory Average history runs 6 years deep, the most recent figure standing at $71.5 million for Q1 2026.

• Quarterly Inventory Average rose 41.68% year-over-year to $71.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.5 million (up 41.68% YoY) and the FY2025 annual result came in at $58.4 million, up 34.29% from the prior year.
• Inventory Average was $71.5 million for Q1 2026 at Xeris Biopharma Holdings, up from $68.1 million in the prior quarter.
• Across five years, Inventory Average topped out at $71.5 million in Q1 2026 and bottomed at $17.4 million in Q2 2022.
• A 5-year average of $41.3 million and a median of $39.9 million in 2024 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2023 — Inventory Average jumped 96.49% — and 2024, when it gained 17.96%.
• Xeris Biopharma Holdings' Inventory Average stood at $22.4 million in 2022, then soared by 71.62% to $38.5 million in 2023, then increased by 21.19% to $46.6 million in 2024, then jumped by 45.92% to $68.1 million in 2025, then gained by 4.97% to $71.5 million in 2026.
• Business Quant data shows XERS's Inventory Average at $71.5 million in Q1 2026, $68.1 million in Q4 2025, and $67.4 million in Q3 2025.